IL17RA and neoplasm: In agreement with the results of immunohistochemical analysis (Figure 1), flow cytometry analysis also revealed that an average of 12% (range 2–19%) of fresh (not cultured) tumor cells expressed IL-17R and 75% of IL-17R+ cells co-expressed GSC markers CD133 and Nestin (Figure 2A).